Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01587313
Recruitment Status : Completed
First Posted : April 30, 2012
Last Update Posted : August 6, 2015
Sponsor:
Information provided by (Responsible Party):
Arbor Pharmaceuticals, Inc.

Brief Summary:
This is a single center, open-label, two-period study. There will be nine healthy human volunteers arbitrarily assigned to one of four groups. The study objective is to compare the action of various combinations of BiDil extended-release capsules and commercial BiDil Tablets in the body over a period of time.

Condition or disease Intervention/treatment Phase
Healthy Drug: Isosorbide dinitrate / hydralazine capsules Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Four-arm, Single Dose, Two-Period, Pharmacokinetic Study of BiDil SR and IR Capsules and Commercial BiDil Tablets
Study Start Date : April 2012
Actual Primary Completion Date : May 2012
Actual Study Completion Date : May 2012

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group 1
ISDN/HYD 2 SR caps crossover to 1 IR cap at 8 am
Drug: Isosorbide dinitrate / hydralazine capsules
Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid
Other Name: BiDil tablets; ISDN/HYD

Experimental: Group 2
ISDN/HYD 2 SR caps crossover to 1 IR cap at 5 pm
Drug: Isosorbide dinitrate / hydralazine capsules
Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid
Other Name: BiDil tablets; ISDN/HYD

Experimental: Group 3
ISDN/HYD 2 SR caps crossover to 1 IR cap at 8 pm
Drug: Isosorbide dinitrate / hydralazine capsules
Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid
Other Name: BiDil tablets; ISDN/HYD

Active Comparator: Group 4
ISDN/HYD 1 IR cap and two SR caps at 8 am crossover to Day 8: BiDil Tablet tid
Drug: Isosorbide dinitrate / hydralazine capsules
Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid
Other Name: BiDil tablets; ISDN/HYD




Primary Outcome Measures :
  1. Area under the plasma/blood concentration versus time curve, as calculated by the linear trapezoidal method for Hydralazine and ISDN and metabolites. [ Time Frame: from time zero (0) to 24 hr ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy, nonsmoking, slow acetylator (as determined by caffeine metabolite assay) males or females between the ages of 18 to 40 years inclusive.
  • Body weight at least 150 pounds and Body Mass Index between 18.5 and 30 kg/m2.
  • Medical history, physical examination, and clinical laboratory test results indicating either normal vital organ/endocrine functions, or no clinically significant abnormalities.
  • Clinical laboratory testing negative for: HIV, Hepatitis B surface antigen and Hepatitis C antibody.
  • Urine testing negative for drugs of abuse (including, but not limited to marijuana, amphetamines, barbiturates and cocaine).
  • Negative urine cotinine test and negative saliva alcohol test.
  • Negative urine HCG test, consistent with no pregnancy (females only).
  • For female subjects, a recent history of menses that is regular for the individual (24 36 day cycles).
  • Females participating in this study must be:
  • unable to have children (e.g., post-menopausal, tubal ligation, hysterectomy) OR
  • willing to remain abstinent [not engage in sexual intercourse for the duration of the screening period and throughout the study, and for 14 days after the last dose] OR
  • willing to use two effective barrier methods of birth control (partner using condom and female using IUD, diaphragm plus spermicide, or contraceptive sponge).
  • Ability to grant voluntary informed consent to participate in the study.

Exclusion Criteria:

  • Known history or presence of any clinically significant medical condition.
  • Known or suspected carcinoma.
  • Use of prescription or OTC drug(s), other than acetaminophen, within two weeks of first dose of study drug and throughout study unless approved by the investigator or sponsor.
  • Use of alcohol or caffeine containing products within 48 hours of each dose of study drug.
  • History of, or evidence of clinically significant medical condition, including, but not limited to hepatic, renal, cardiac, vascular, gastrointestinal, or thyroid disease, diabetes, epilepsy, respiratory or hematological disease, acute narrow angle glaucoma or psychiatric disorder which, in the opinion of the Investigator would confound the study results or present a risk to the subject.
  • History of alcohol or drug abuse within one year of study participation.
  • Presence of, or known hypersensitivity, allergy, idiosyncratic reaction or adverse reaction to caffeine, ISDN, hydralazine HCl, or any compounds with similar chemical characteristics.
  • Received an investigational drug within 30 days of the first dose in this study.
  • Blood pressure less than 110/70 mm Hg at screening or at Day 1 prior to dosing.
  • Donated one pint or more of blood or donated platelets within 30 days of the first dose in this study.
  • Any subject who, in the opinion of the Investigator, cannot follow instructions.
  • With regard to females; pregnancy, lactation, or the use of hormonal contraception.
  • History of lupus erythematous or lupus like syndrome.
  • Use of herbal preparations or use of phosphodiesterase inhibitors.
  • Employee of the Sponsor or CRO.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01587313


Locations
Layout table for location information
United States, New Jersey
Frontage Cinical Services
Hackensack, New Jersey, United States, 07601
Sponsors and Collaborators
Arbor Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Gregory J Tracey, MD Frontage Laboratories, Inc.

Layout table for additonal information
Responsible Party: Arbor Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01587313     History of Changes
Other Study ID Numbers: AR06.004
First Posted: April 30, 2012    Key Record Dates
Last Update Posted: August 6, 2015
Last Verified: August 2015
Keywords provided by Arbor Pharmaceuticals, Inc.:
hydralazine
isosorbide
bidil
volunteers
pharmacokinetic profile
Additional relevant MeSH terms:
Layout table for MeSH terms
Hydralazine
Isosorbide
Isosorbide Dinitrate
Isosorbide-5-mononitrate
Diuretics, Osmotic
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Vasodilator Agents
Nitric Oxide Donors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents